Cambridge, MA - CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, today introduced software to enable analyses of operational data using a risk-based monitoring approach at DIA 2015. The new software includes Key Risk Indicators (KRIs) that perfectly complement the statistical analysis of clinical data. This KRI+ approach allows sponsors and CROs to set their own subjective threshold levels, while also statistically examining data objectively to show how a single site's KRIs can be judged against results across all other sites. CluePoints will demonstrate its latest software offering on booth #1511 at the DIA 2015 51st Annual Meeting in Washington, DC.
CluePoints' award-winning SMART™ Engine lies at the heart of the solution and has been designed to offer independent and objective interrogation of clinical data, leaving no stone unturned in assessing data quality and integrity. The enhancement of the engine with the KRI+ approach provides users with the powers of statistical analysis alongside their own triggers for action across key operational variables. This means that more frequent operational analyses can be conducted, and, when coupled with exhaustive interrogation of all clinical data, the software ensures that sponsors and CROs are able to de-risk studies and improve data quality and integrity using an automated approach. Additionally, the new software will soon support an online, customizable version of the Transcelerate-recommended Risk-Assessment Categorization Tool (RACT), allowing the CluePoints monitoring platform to provide upfront study/site risk assessment.
"With our latest software release we wanted to enable our customers to incorporate objective statistical analysis, while also allowing users to assess key operational variables to provide the most meticulous interrogation of all clinical data", comments FranÒ«ois Torche, CEO, CluePoints. "This is our latest advancement in helping our customers move towards 0% SDV and 100% data quality oversight, enabling clinical workflows to be streamlined and resources to be more effectively managed by focusing attention on the sites and data that really matter."
At the DIA 2015 Annual Meeting CluePoints' data quality thought leaders will present two interactive sessions. Delegates can learn about 'Ensuring Data Quality and Detecting Potential Fraud' on Tuesday, June 16 at 8:00-9:30am (#209, Track 07A) and 'Integrating Central Statistical Monitoring in a Quality by Design Approach for Clinical Trials' on Wednesday, June 17 at 3:30-5:00pm (#391 Track 15).
For further information on CluePoints or to request a demo of the new software, please visit booth #1511 at the DIA 2015 Annual Meeting or www.CluePoints.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.